NASDAQ:ATNF 180 Life Sciences (ATNF) Stock Forecast, Price & News $1.16 -0.03 (-2.52%) (As of 03:20 PM ET) Add Compare Share Share Today's Range$1.13▼$1.2450-Day Range$0.97▼$1.9552-Week Range$0.94▼$39.80Volume97,987 shsAverage Volume1.85 million shsMarket Capitalization$4.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 180 Life Sciences MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 2 Articles This WeekInsider TradingAcquiring Shares$65,421 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for 180 Life Sciences. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.96% of the float of 180 Life Sciences has been sold short.Short Interest Ratio / Days to Cover180 Life Sciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 180 Life Sciences has recently decreased by 13.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield180 Life Sciences does not currently pay a dividend.Dividend Growth180 Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNF. Previous Next 3.1 News and Social Media Coverage News Sentiment180 Life Sciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 180 Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for ATNF on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows5 people have added 180 Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 180 Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,421.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of 180 Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 15.30% of the stock of 180 Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of 180 Life Sciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 180 Life Sciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio180 Life Sciences has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 180 Life Sciences (NASDAQ:ATNF) Stock180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.Read More Receive ATNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATNF Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAnalyzing Antibe Therapeutics (OTCMKTS:ATBPD) & 180 Life Sciences (NASDAQ:ATNF)May 21, 2023 | americanbankingnews.comInsider Buying: 180 Life Sciences Corp. (NASDAQ:ATNF) CEO Buys 40,000 Shares of StockJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. April 27, 2023 | americanbankingnews.com180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest UpdateApril 17, 2023 | americanbankingnews.com180 Life Sciences Corp. (NASDAQ:ATNF) Sees Significant Increase in Short InterestApril 10, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private PlacementApril 5, 2023 | finance.yahoo.com180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private PlacementApril 5, 2023 | investorplace.comWhy Is 180 Life Sciences (ATNF) Stock Up 30% Today?June 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. February 28, 2023 | finance.yahoo.com180 Life Sciences Announces Presentation at the Gordon ConferenceFebruary 27, 2023 | finance.yahoo.com180 Life Sciences Announces Presentation at the Gordon ConferenceFebruary 23, 2023 | finance.yahoo.com180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and ApplicationFebruary 23, 2023 | seekingalpha.com180 Life Sciences stock dips as recruitment in trial for Frozen shoulder closes amid challengesFebruary 23, 2023 | seekingalpha.com180 Life Sciences to get US patent linked to treating hand disorder DupuytrenFebruary 23, 2023 | finance.yahoo.com180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and ApplicationFebruary 22, 2023 | benzinga.com180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder TrialFebruary 22, 2023 | finance.yahoo.com180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder TrialJanuary 25, 2023 | finance.yahoo.com180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s DiseaseJanuary 25, 2023 | msn.com180 Life Sciences up 12% on tumor necrosis factor as target for Dupuytren’s diseaseJanuary 25, 2023 | finance.yahoo.com180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s DiseaseJanuary 17, 2023 | finance.yahoo.com180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United KingdomJanuary 10, 2023 | wsj.comNewman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)January 5, 2023 | finance.yahoo.com180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price RequirementJanuary 4, 2023 | au.finance.yahoo.com180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s DiseaseJanuary 4, 2023 | finance.yahoo.com180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s DiseaseJanuary 3, 2023 | benzinga.comThinking about buying stock in Mullen Automotive, SWVL Holdings, 180 Life Sciences, Alibaba, or Pinterest?December 23, 2022 | finance.yahoo.com180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSee More Headlines ATNF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATNF Company Calendar Today6/02/2023Next Earnings (Estimated)6/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNF CUSIPN/A CIK1690080 Webwww.kblmerger.com Phone(650) 507-0669FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-119.88% Return on Assets-85.65% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book0.69Miscellaneous Outstanding Shares4,150,000Free Float3,902,000Market Cap$4.94 million OptionableNot Optionable Beta0.53 Key ExecutivesJim N. WoodyChief Executive Officer & DirectorOzan PamirChief Financial OfficerJonathan B. RothbardChief Scientific OfficerJason AssadDirector-Investor RelationsKey CompetitorsAptinyxNASDAQ:APTXArtelo BiosciencesNASDAQ:ARTLQualigen TherapeuticsNASDAQ:QLGNXenetic BiosciencesNASDAQ:XBIOOncorusNASDAQ:ONCRView All CompetitorsInsiders & InstitutionsJr. Donald A McgovernBought 10,000 shares on 5/31/2023Total: $11,500.00 ($1.15/share)James N WoodyBought 40,000 shares on 5/18/2023Total: $41,200.00 ($1.03/share)Pamela G MarroneBought 7,082 shares on 5/18/2023Total: $7,506.92 ($1.06/share)Ozan PamirBought 5,162 shares on 5/18/2023Total: $5,213.62 ($1.01/share)Cubist Systematic Strategies LLCBought 23,521 shares on 5/15/2023Ownership: 0.628%View All Insider TransactionsView All Institutional Transactions ATNF Stock - Frequently Asked Questions Should I buy or sell 180 Life Sciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 180 Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATNF shares. View ATNF analyst ratings or view top-rated stocks. How have ATNF shares performed in 2023? 180 Life Sciences' stock was trading at $3.39 at the start of the year. Since then, ATNF shares have decreased by 64.9% and is now trading at $1.19. View the best growth stocks for 2023 here. Are investors shorting 180 Life Sciences? 180 Life Sciences saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 95,400 shares, a drop of 13.2% from the April 30th total of 109,900 shares. Based on an average daily volume of 871,400 shares, the short-interest ratio is presently 0.1 days. Approximately 2.0% of the shares of the stock are sold short. View 180 Life Sciences' Short Interest. When is 180 Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023. View our ATNF earnings forecast. When did 180 Life Sciences' stock split? 180 Life Sciences shares reverse split before market open on Monday, December 19th 2022. The 1-20 reverse split was announced on Monday, December 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is 180 Life Sciences' stock symbol? 180 Life Sciences trades on the NASDAQ under the ticker symbol "ATNF." Who are 180 Life Sciences' major shareholders? 180 Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.06%), Cubist Systematic Strategies LLC (0.63%), Two Sigma Investments LP (0.38%) and Simplex Trading LLC (0.00%). Insiders that own company stock include James N Woody, Jr Donald A Mcgovern, Marlene Krauss, Ozan Pamir, Pamela G Marrone and Quan Anh Vu. View institutional ownership trends. How do I buy shares of 180 Life Sciences? Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 180 Life Sciences' stock price today? One share of ATNF stock can currently be purchased for approximately $1.19. How much money does 180 Life Sciences make? 180 Life Sciences (NASDAQ:ATNF) has a market capitalization of $4.94 million. The company earns $-38,730,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. How can I contact 180 Life Sciences? 180 Life Sciences' mailing address is 30 PARK PLACE SUITE 45E, NEW YORK NY, 10007. The official website for the company is www.kblmerger.com. The company can be reached via phone at (650) 507-0669 or via email at jason@180lifesciences.com. This page (NASDAQ:ATNF) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.